Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity
- Others:
- Défense innée et inflammation ; Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Cellule Pasteur UPMC ; Institut Pasteur [Paris]-Sorbonne Université (SU)
- Université Paris Descartes - Paris 5 (UPD5)
- Service de pneumologie [CHU Cochin] ; Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Institut de pharmacologie moléculaire et cellulaire (IPMC) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- Service de Pneumologie et d'Allergologie Pédiatriques ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Régulation du transport anionique transépithélial : de la recherche fondamentale aux pathologies épithéliales (UMR_S 806) ; Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- National Research Institute of Mother and Child [Warsaw, Poland]
- Service de Bactériologie [CHU Cochin, AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- This study was supported by France 'Vaincre la Mucoviscidose' and 'DIM Malinf-Region Ile de France' foundation.
- We thank Dr R. Ramphal (University of Florida, Gainesville, FL, USA), Dr T. Msadek (Institut Pasteur, Paris), Dr E. Pearlman (Case Western Reserve University, Cleveland, OH, USA), Dr J.C. Olson (West Virginia University, Morgantown, WV, USA), Dr P. Peris (University of València, Spain), Dr M. Gelb (University of Washington, Seattle, WA, USA) for providing PA and SA strains as well as substrate for sPLA2 activity assay and RO032007A compound; Dr C. Schmitt (Hôpital Trousseau, Paris) for providing expectorations of children patients; V. Balloy and M. Nahori (Institut Pasteur, Paris) for technical assistance with intratracheal and intravenous instillation and C. Payre for helpful advices in sPLA2 analyses.
Description
Young cystic fibrosis (CF) patients' airways are mainly colonized by Staphylococcus aureus, while Pseudomonas aeruginosa predominates in adults. However, the mechanisms behind this infection switch are unclear. Here, we show that levels of type-IIA-secreted phospholipase A2 (sPLA2-IIA, a host enzyme with bactericidal activity) increase in expectorations of CF patients in an age-dependent manner. These levels are sufficient to kill S. aureus, with marginal effects on P. aeruginosa strains. P. aeruginosa laboratory strains and isolates from CF patients induce sPLA2-IIA expression in bronchial epithelial cells from CF patients (these cells are a major source of the enzyme). In an animal model of lung infection, P. aeruginosa induces sPLA2-IIA production that favours S. aureus killing. We suggest that sPLA2-IIA induction by P. aeruginosa contributes to S. aureus eradication in CF airways. Our results indicate that a bacterium can eradicate another bacterium by manipulating the host immunity.
Abstract
International audience
Additional details
- URL
- https://hal-pasteur.archives-ouvertes.fr/pasteur-02863033
- URN
- urn:oai:HAL:pasteur-02863033v1
- Origin repository
- UNICA